Comparative Pharmacology
Head-to-head clinical analysis: ZOFRAN versus ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ZOFRAN versus ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER.
ZOFRAN vs ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin 5-HT3 receptor antagonist; blocks serotonin binding at 5-HT3 receptors in the chemoreceptor trigger zone and gastrointestinal tract, thereby inhibiting emesis.
Ondansetron is a selective serotonin 5-HT3 receptor antagonist. It blocks the action of serotonin at 5-HT3 receptors in the chemoreceptor trigger zone (CTZ) and gastrointestinal tract, thereby preventing nausea and vomiting. Dextrose provides caloric support.
8 mg orally or intravenously 30 minutes before chemotherapy; may repeat 8 mg orally 8 hours after first dose, then 8 mg orally every 12 hours for 1-2 days.
4 mg IV or IM every 8 hours as needed; for prevention of chemotherapy-induced nausea and vomiting, 0.15 mg/kg IV up to 16 mg per dose, infused over 15 minutes, given 30 minutes before chemotherapy, then repeat at 4 and 8 hours after first dose, or as a single 32 mg IV dose over 15 minutes immediately before chemotherapy.
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours in adults; in children (1 month to 12 years), half-life averages 2.5 hours; in elderly (≥75 years), half-life may be prolonged to 5.5 hours. Clinically, repeated dosing every 8 hours maintains antiemetic coverage.
Terminal elimination half-life is approximately 3–4 hours in adults, though may be prolonged to 5–8 hours in severe hepatic impairment (Child-Pugh class C) or elderly patients.
Approximately 5% of the dose is excreted unchanged in urine; the remainder undergoes extensive hepatic metabolism via CYP1A1, CYP1A2, CYP3A4, and flavin-containing monooxygenases, with metabolites excreted in urine (about 44-60% of total clearance) and feces (about 25-45%). Less than 10% is eliminated in bile.
Primarily hepatic metabolism (~95%) via CYP1A2, CYP2D6, and CYP3A4; less than 10% excreted unchanged in urine. Fecal excretion accounts for ~20% of metabolites.
Category C
Category C
Antiemetic (5-HT3 Antagonist)
Antiemetic (5-HT3 Antagonist)